Compare HAFC & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | FLGT |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.9M | 697.3M |
| IPO Year | 1996 | 2016 |
| Metric | HAFC | FLGT |
|---|---|---|
| Price | $29.18 | $26.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $28.50 | $28.33 |
| AVG Volume (30 Days) | 172.8K | ★ 309.8K |
| Earning Date | 01-27-2026 | 11-07-2025 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 15.36 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | $246,352,000.00 | ★ $315,549,000.00 |
| Revenue This Year | $19.61 | $16.84 |
| Revenue Next Year | $11.05 | $9.74 |
| P/E Ratio | $11.83 | ★ N/A |
| Revenue Growth | 5.84 | ★ 13.61 |
| 52 Week Low | $19.25 | $14.57 |
| 52 Week High | $29.13 | $31.04 |
| Indicator | HAFC | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 71.57 | 44.11 |
| Support Level | $28.00 | $27.52 |
| Resistance Level | $29.27 | $31.04 |
| Average True Range (ATR) | 0.60 | 0.83 |
| MACD | 0.09 | -0.49 |
| Stochastic Oscillator | 95.25 | 2.64 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.